Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adrian Caplanusi

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Human Vaccines & Immunotherapeutics|July 16, 2015
Safety and persistence of the humoral and cellular immune responses induced by 2 doses of an AS03-adjuvanted A(H1N1)pdm09 pandemic influenza vaccine administered to infants, children and adolescents: Two open, uncontrolled studiesJosé Garcia-Sicilia, Javier Arístegui, Félix Omeñaca, et al.
The Pediatric Infectious Disease Journal|June 13, 2015
Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine in Children 6 Months to 17 Years of Age, Previously Vaccinated with an AS03-Adjuvanted A(H1N1)Pdm09 Vaccine: Two Open-label, Randomized TrialsTimo Vesikari, Jan Hendrik Richardus, Johan Berglund, et al.
Experimental Cell Research|March 5, 2008
Differential subcellular membrane recruitment of Src may specify its downstream signallingPhilippe de Diesbach, Thierry Medts, Sarah Carpentier, et al.
BMC Infectious Diseases|September 18, 2013
Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trialsOdile Launay, Xavier Duval, Serge Fitoussi, et al.
Journal of the American Society of Nephrology : JASN|February 6, 2010
ZONAB promotes proliferation and represses differentiation of proximal tubule epithelial cellsWânia R Lima, Kleber S Parreira, Olivier Devuyst, et al.
The New England Journal of Medicine|December 17, 2013
Vaccine for prevention of mild and moderate-to-severe influenza in childrenVarsha K Jain, Luis Rivera, Khalequ Zaman, et al.
Journal of the Pediatric Infectious Diseases Society|March 9, 2019
Immunogenicity and Safety of a Measles-Mumps-Rubella Vaccine Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III, Randomized, Noninferiority, Lot-to-Lot Consistency StudyNicola P Klein, Remon Abu-Elyazeed, Michael Povey, et al.
The Lancet. Infectious Diseases|March 23, 2013
AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trialJanet E McElhaney, Jiri Beran, Jeanne-Marie Devaster, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Human Vaccines & Immunotherapeutics|July 16, 2015
Safety and persistence of the humoral and cellular immune responses induced by 2 doses of an AS03-adjuvanted A(H1N1)pdm09 pandemic influenza vaccine administered to infants, children and adolescents: Two open, uncontrolled studiesJosé Garcia-Sicilia, Javier Arístegui, Félix Omeñaca, et al.
The Pediatric Infectious Disease Journal|June 13, 2015
Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine in Children 6 Months to 17 Years of Age, Previously Vaccinated with an AS03-Adjuvanted A(H1N1)Pdm09 Vaccine: Two Open-label, Randomized TrialsTimo Vesikari, Jan Hendrik Richardus, Johan Berglund, et al.
Experimental Cell Research|March 5, 2008
Differential subcellular membrane recruitment of Src may specify its downstream signallingPhilippe de Diesbach, Thierry Medts, Sarah Carpentier, et al.
BMC Infectious Diseases|September 18, 2013
Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trialsOdile Launay, Xavier Duval, Serge Fitoussi, et al.
Journal of the American Society of Nephrology : JASN|February 6, 2010
ZONAB promotes proliferation and represses differentiation of proximal tubule epithelial cellsWânia R Lima, Kleber S Parreira, Olivier Devuyst, et al.
The New England Journal of Medicine|December 17, 2013
Vaccine for prevention of mild and moderate-to-severe influenza in childrenVarsha K Jain, Luis Rivera, Khalequ Zaman, et al.
Journal of the Pediatric Infectious Diseases Society|March 9, 2019
Immunogenicity and Safety of a Measles-Mumps-Rubella Vaccine Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III, Randomized, Noninferiority, Lot-to-Lot Consistency StudyNicola P Klein, Remon Abu-Elyazeed, Michael Povey, et al.
The Lancet. Infectious Diseases|March 23, 2013
AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trialJanet E McElhaney, Jiri Beran, Jeanne-Marie Devaster, et al.
Pageof 2